TY - JOUR
T1 - Bioluminescent Francisella tularensis SCHU S4 enables non-invasive tracking of bacterial dissemination and the evaluation of antibiotics in an inhalational mouse model of tularaemia
AU - Hall, Charlotte
AU - Flick-Smith, Helen
AU - Harding, Sarah
AU - Atkins, Helen
AU - Titball, Richard
N1 - This document is the Accepted Manuscript version of the following article: Hall CA, Flick-Smith HC, Harding SV, Atkins HS, and Titball RW. 2016. "A bioluminescent Francisella tularensis SCHU S4 strain enables noninvasive tracking of bacterial dissemination and the evaluation of antibiotics in an inhalational mouse model of tularemia", Antimicrob Agents Chemother 60:7206–7215.
The version of record is available online at doi:10.1128/AAC.01586-16.
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Bioluminescence imaging (BLI) enables real-time, noninvasive tracking of infection in vivo and longitudinal infection studies. In this study, a bioluminescent Francisella tularensis strain, SCHU S4-lux, was used to develop an inhalational infection model in BALB/c mice. Mice were infected intranasally, and the progression of infection was monitored in real time using BLI. A bioluminescent signal was detectable from 3 days postinfection (3 dpi), initially in the spleen and then in the liver and lymph nodes, before finally becoming systemic. The level of bioluminescent signal correlated with bacterial numbers in vivo, enabling noninvasive quantification of bacterial burdens in tissues. Treatment with levofloxacin (commencing at 4 dpi) significantly reduced the BLI signal. Furthermore, BLI was able to distinguish noninvasively between different levofloxacin treatment regimens and to identify sites of relapse following treatment cessation. These data demonstrate that BLI and SCHU S4-lux are suitable for the study of F. tularensis pathogenesis and the evaluation of therapeutics for tularemia.
AB - Bioluminescence imaging (BLI) enables real-time, noninvasive tracking of infection in vivo and longitudinal infection studies. In this study, a bioluminescent Francisella tularensis strain, SCHU S4-lux, was used to develop an inhalational infection model in BALB/c mice. Mice were infected intranasally, and the progression of infection was monitored in real time using BLI. A bioluminescent signal was detectable from 3 days postinfection (3 dpi), initially in the spleen and then in the liver and lymph nodes, before finally becoming systemic. The level of bioluminescent signal correlated with bacterial numbers in vivo, enabling noninvasive quantification of bacterial burdens in tissues. Treatment with levofloxacin (commencing at 4 dpi) significantly reduced the BLI signal. Furthermore, BLI was able to distinguish noninvasively between different levofloxacin treatment regimens and to identify sites of relapse following treatment cessation. These data demonstrate that BLI and SCHU S4-lux are suitable for the study of F. tularensis pathogenesis and the evaluation of therapeutics for tularemia.
U2 - 10.1128/AAC.01586-16
DO - 10.1128/AAC.01586-16
M3 - Article
VL - 60
SP - 7206
EP - 7215
JO - Antimicrobial Agents and Chemotherapy
JF - Antimicrobial Agents and Chemotherapy
SN - 0066-4804
IS - 12
ER -